- Home
- CEPU vs ETNB Comparison
CEPU vs ETNB Comparison
Compare CEPU & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEPU
- ETNB
- Stock Information
- Founded
- CEPU 1989
- ETNB 2018
- Country
- CEPU Argentina
- ETNB United States
- Employees
- CEPU N/A
- ETNB N/A
- Industry
- CEPU Electric Utilities: Central
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- CEPU Utilities
- ETNB Health Care
- Exchange
- CEPU Nasdaq
- ETNB Nasdaq
- Market Cap
- CEPU 1.6B
- ETNB 1.5B
- IPO Year
- CEPU 2018
- ETNB 2019
- Fundamental
- Price
- CEPU $10.11
- ETNB $8.87
- Analyst Decision
- CEPU Hold
- ETNB Strong Buy
- Analyst Count
- CEPU 1
- ETNB 10
- Target Price
- CEPU $12.00
- ETNB $27.22
- AVG Volume (30 Days)
- CEPU 261.2K
- ETNB 1.5M
- Earning Date
- CEPU 08-11-2025
- ETNB 11-06-2025
- Dividend Yield
- CEPU 3.06%
- ETNB N/A
- EPS Growth
- CEPU N/A
- ETNB N/A
- EPS
- CEPU 0.12
- ETNB N/A
- Revenue
- CEPU $628,806,380.00
- ETNB N/A
- Revenue This Year
- CEPU $11.09
- ETNB N/A
- Revenue Next Year
- CEPU $10.25
- ETNB N/A
- P/E Ratio
- CEPU $10.42
- ETNB N/A
- Revenue Growth
- CEPU N/A
- ETNB N/A
- 52 Week Low
- CEPU $8.65
- ETNB $4.16
- 52 Week High
- CEPU $16.60
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- CEPU 35.65
- ETNB 43.45
- Support Level
- CEPU $9.97
- ETNB $8.46
- Resistance Level
- CEPU $10.66
- ETNB $9.47
- Average True Range (ATR)
- CEPU 0.55
- ETNB 0.46
- MACD
- CEPU -0.10
- ETNB -0.02
- Stochastic Oscillator
- CEPU 6.41
- ETNB 33.33
About CEPU Central Puerto S.A. (each represents ten)
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).